Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Abstract | BACKGROUND AND OBJECTIVE: METHODS: First of all, we have examined 11 transporters, ABCB1 ( P-glycoprotein: P-gp), ABCG2 ( breast cancer resistance protein: BCRP), SLC22A6 ( organic anion transporter 1: OAT1), SLC22A8 ( organic anion transporter 3: OAT3), SLCO1B1 (organic anion transporting polypeptide 1B1: OATP1B1), SLCO1B3 (organic anion transporting polypeptide 1B3: OATP1B3), SLCO2B1 (organic anion transporting polypeptide 2B1: OATP2B1), SLC22A1 ( organic cation transporter 1: OCT1), SLC22A2 ( organic cation transporter 2: OCT2), ABCB11 ( bile-salt export pump: BSEP), and ABCC2 ( multidrug resistance associated protein 2: MRP2) to clarify which of them would be candidates that might recognize BPS as their substrate in transporter-expressing LLC-PK1, S2, and HEK293 cells as well as in membrane vesicles. Furthermore, we determined whether the transport of BPS was inhibited by the typical inhibitors of each transporter, i.e., verapamil for P-gp, Ko143 for BCRP, probenecid for OAT3, rifampicin for OATP1B1 and OATP1B3, cyclosporine for BSEP, and sulfobromophthalein (BSP) for MRP2. RESULTS: The results obtained showed that P-gp, BCRP, OAT3, OATP1B1, OATP1B3, BSEP and MRP2 might be candidates for BPS transporters. From the further evaluation with the typical inhibitors of each transporter, it was confirmed that BPS is a substrate for P-gp, BCRP, OAT3, OATP1B1, OATP1B3 and MRP2, because the typical inhibitor, cyclosporine, had no effects on BPS transport by BSEP. CONCLUSIONS: BPS is a substrate of 6 transporters: P-gp, BCRP, OAT3, OATP1B1, OATP1B3, and MRP2, because their expressing cells and vesicles transported BPS more than in the controls, and BPS transport activities were reduced by the typical inhibitors of tested transporters. Although there are no reports regarding drug-drug interactions between BPS and possible combination drugs expected due to transporters, it may be necessary to notice that that substrates or inhibitors for the 6 mentioned transporters may have effects on pharmacokinetics of BPS when co-administered.
|
Authors | Keiyu Oshida, Masahiro Shimamura, Kazuhiro Seya, Akihiro Ando, Yohei Miyamoto |
Journal | European journal of drug metabolism and pharmacokinetics
(Eur J Drug Metab Pharmacokinet)
Vol. 42
Issue 1
Pg. 117-128
(Feb 2017)
ISSN: 2107-0180 [Electronic] France |
PMID | 26961540
(Publication Type: Journal Article)
|
Chemical References |
- ABCC2 protein, human
- Membrane Transport Proteins
- Multidrug Resistance-Associated Protein 2
- beraprost
- Epoprostenol
|
Topics |
- Animals
- Biological Transport
- Cells, Cultured
- Drug Interactions
- Epoprostenol
(analogs & derivatives, pharmacokinetics)
- Humans
- Membrane Transport Proteins
(metabolism)
- Multidrug Resistance-Associated Protein 2
- Swine
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|